Amgen stock dips as HSBC cuts rating and trims price target
Published on 09/10/2026 at 14:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen Inc. stock (ISIN US0311621009) is under renewed scrutiny after HSBC downgraded the shares to Hold on September 10, 2026 and cut its price target from USD 445 to USD 425, citing valuation concerns as the stock trades close to fair value.Investing.com highlights that the downgrade comes after a period of strong operational execution and positive estimate revisions, leaving near-term upside more limited.
HSBC downgrade shifts sentiment
According to Investing.com on September 10, 2026, HSBC analyst Morten Herholdt moved Amgen from Buy to Hold and reduced the target price to USD 425 from USD 445, arguing that the shares have re-rated on strong execution and now trade close to the firm’s valuation range.
The same review notes that the stock’s re-rating over the next 12 months will hinge heavily on the outcome of the MariTide obesity trial, a segment described as an increasingly crowded space with intensifying competition.Investing.com points out that this trial readout is a key catalyst for the stock and a potential risk factor if results fail to differentiate the therapy.
Strong second-quarter figures and raised guidance
Beyond the rating change, Amgen’s latest reported numbers still show solid underlying growth. Based on the company’s most recent quarterly disclosure for the period ending June 30, 2026, Amgen generated revenue of USD 10.05 billion in the second quarter of 2026, up from USD 9.17 billion in the prior-year quarter, which represents a 9.6 percent year-over-year increase.Ad-hoc-news reports that earnings per share for that quarter came in at USD 6.29, beating the consensus estimate of USD 5.62 by USD 0.67, while net margin stood at 22.95 percent.
According to the same MarketBeat-based overview cited by Ad-hoc-news, Amgen set its fiscal year 2026 earnings guidance at USD 22.30 to USD 23.50 per share, with analysts expecting around USD 22.97 per share for the current year. That guidance range implies mid-single-digit to high-single-digit EPS growth compared with historical levels and underpins the valuation discussion now driving the HSBC downgrade.
Dividend remains an income anchor
Dividend income continues to play a role in the investment case. The MarketBeat overview referenced by Ad-hoc-news indicates that Amgen recently declared a quarterly dividend of USD 2.52 per share, implying an annualized payment of USD 10.08 and a dividend yield of about 2.6 percent based on the prevailing share price at the time of that announcement.
For income-oriented investors, that combination of a roughly 2.6 percent yield and EPS guidance in the low-USD-20s suggests that the payout remains covered by earnings, although the HSBC move signals that, in their view, valuation now leaves less room for capital gains unless upcoming trial data surprise positively.
Analyst landscape turns more cautious
The HSBC downgrade slots into a broader pattern of reassessed expectations. As Investing.com reports on September 10, 2026, several houses have recently adjusted their Amgen price targets: Wells Fargo lifted its target to USD 435, Cantor Fitzgerald raised its target to USD 400, and Guggenheim increased its target to USD 388 following Amgen’s second-quarter beat.
At the same time, analyst consensus data compiled by MarketBeat show that Amgen now carries a Moderate Buy consensus with an average price target of around USD 381.68, implying a modest downside from some of the recent trading levels.MarketBeat notes that despite ongoing institutional interest, the balance of ratings now leans toward Hold, reflecting a more cautious stance as valuation and trial risk are weighed together.
Stock performance and recent volatility
Recent sessions have illustrated how quickly sentiment can swing. In the latest completed Nasdaq trading session before September 9, 2026, Amgen shares closed at about USD 393.17, marking a decline of 10.1 percent from the prior day and positioning the stock near a short-term resistance zone yet still above a cited 200-day simple moving average around USD 359.Ad-hoc-news attributes that sharp drop in part to trial read-through and concerns around Tavneos-related risk.
On September 10, 2026, European trading data cited by Goldesel showed Amgen quoted around EUR 337.05, up 0.6 percent in Frankfurt at 09:38 local time, while the previous U.S. close stood at USD 391.27 on Nasdaq. In that snapshot, the year-to-date price gain was around 21 percent, illustrating how the stock has already re-rated substantially before the latest downgrade.
Next earnings date as the next checkpoint
The next major scheduled update for investors is the upcoming quarterly earnings release. Zacks’ earnings calendar indicates that Amgen’s next earnings report is expected on November 3, 2026 for the quarter ending in September 2026.Zacks notes that the consensus EPS estimate for that quarter stands at USD 5.69, compared with the USD 6.29 delivered in the June quarter.
Because the Zacks date is described as an estimated report date, investors will watch for confirmation from Amgen’s own investor-relations communication closer to the event, but the calendar nonetheless provides a working timetable for when fresh fundamental data and guidance updates may influence the stock again.
Amgen stock and investor takeaway
With Amgen stock having delivered a roughly 9.6 percent revenue increase in the second quarter of 2026 and beating EPS expectations by USD 0.67 per share, while guiding fiscal year 2026 earnings to a range of USD 22.30 to USD 23.50 per share, the downgrade from HSBC to Hold with a reduced target of USD 425 underscores how much of that operational strength the market has already priced in.Investing.com and Ad-hoc-news together show that the key questions now center on trial outcomes and the sustainability of growth rather than on the strength of the last reported quarter.
Amgen stock - key data
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: AMGN
- Trading venue: Nasdaq
- Price (as of September 9, 2026): 393.17 USD
- Market capitalization: [value] USD (as of September 9, 2026)
- Sector / Industry: Biotechnology / Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: November 3, 2026
